FXYD2 and nonpapillary renal cell carcinoma: Stratified survival analyses under different clinicopathological circumstances, including gender, age, with or without pharmaceutical intervention, with or without smoking, stage, grade, and with or without metastasis, indicated that low FXYD2 expression was associated with poor overall survival in ccRCC patients in keeping with the previous survival analyses (Figures 4(a)–4(d), Figures S3(a)-S3(c)).